Oxford Gene Technology (OGT) and the Wellcome Trust Sanger Institute will develop a single-platform microarray to test for genetic defects in unborn children. The goal of is to develop and validate a microarray to specifically target a number of key prenatal syndromes.
OGT will design and develop the 60-mer oligonucleotide microarray using its ink jet in situ synthesis platform and work. The company will work with the Sanger Institute’s clinical network to target the most appropriate syndromes.